Ring Nitrogen Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 546/51)
  • Patent number: 8927564
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 6, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald G. Payan, Sylvia Braselmann
  • Patent number: 8765432
    Abstract: The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: July 1, 2014
    Assignee: Oligasis, LLC
    Inventors: Stephen A. Charles, D. Victor Perlroth
  • Publication number: 20130237524
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 12, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald G. Payan, Sylvia Braselmann
  • Publication number: 20120283284
    Abstract: The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers.
    Type: Application
    Filed: November 4, 2010
    Publication date: November 8, 2012
    Applicant: Kunming Institute of Botany, The Chinese Academy of Sciences
    Inventors: Xiaodong Luo, Tao Feng, Yan Li, Yuanyuan Wang, Xianghai Cai, Yaping Liu
  • Publication number: 20120232241
    Abstract: The present invention relates to compounds of the formula (1), formula (2), formula (3) and formula (4) which are suitable for use in electronic devices, in particular organic electroluminescent devices.
    Type: Application
    Filed: October 20, 2010
    Publication date: September 13, 2012
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Philipp Stoessel, Esther Breuning, Dominik Joosten, Christof Pflumm, Amir Hossain Parham
  • Patent number: 7994186
    Abstract: A camptothecin-containing pharmaceutical composition which contains: (a) camptothecin or a derivative thereof, and (b) one or more compounds selected from among ascorbic acid or a salt thereof, sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and ?-thioglycerin. The pharmaceutical composition is useful in that, after storage for a long period of time or under light-irradiation conditions, camptothecin or a derivative thereof contained therein undergoes minimum degradation.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: August 9, 2011
    Assignee: Kabushiki Kaisha Yakult Honsha
    Inventors: Masako Nakazawa, Ritsuo Aiyama, Masato Nagaoka
  • Patent number: 7910593
    Abstract: An objective of the present invention is to provide water-soluble prodrugs that can be administered parenterally, and which show excellent water solubility and small interspecies or individual differences and are rapidly converted to the active form by chemical conversion. This invention provides water-soluble prodrugs represented by formula (1), or pharmaceutically acceptable salts, or hydrates or solvates thereof, (wherein, R1 represents a hydrogen atom, or C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or sulfonyl group; and Y represents a residue of a compound represented by Y—OH comprising an alcoholic hydroxyl group).
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: March 22, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Isao Umeda, Jun Ohwada, Sawako Ozawa
  • Publication number: 20110059977
    Abstract: The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and R1, R2, R3, R4, R5, R6, R7 and R8 represent in particular a hydrogen atom.
    Type: Application
    Filed: March 22, 2007
    Publication date: March 10, 2011
    Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.)
    Inventors: Alain Robert Francois Maxime Fournet, Delphine Lagoutte, Erwan Poupon, Flor Soriano-Agaton
  • Publication number: 20100168149
    Abstract: Compound of formula (I): wherein: R1, R2, R3, R4, R5, R80, R90, R81, R91, Alk and G are as defined in the description. Medicinal products containing the same which are useful in the treatment of cancer diseases.
    Type: Application
    Filed: August 4, 2006
    Publication date: July 1, 2010
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, John Hickman, Stephane Leonce
  • Publication number: 20100168150
    Abstract: Compound of formula (I): wherein: R1, R2, R3, R4, R5, R80, R90, R81, R91, Alk, Alk?, X, X? and G are as defined in the description. Medicinal products containing the same which are useful in the treatment of cancer diseases.
    Type: Application
    Filed: August 4, 2006
    Publication date: July 1, 2010
    Applicant: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, John Hickman, Stephane Leonce
  • Publication number: 20100113498
    Abstract: The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.
    Type: Application
    Filed: December 17, 2007
    Publication date: May 6, 2010
    Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Lihong Hu, Xu Shen, Hualiang Jiang, Liguang Lou
  • Patent number: 7605262
    Abstract: 4-O esters of podophyllotoxin and 4?-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4?-demethylepipodophyllotoxin. The compounds are useful for treating cancer.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: October 20, 2009
    Assignees: Sutter West Bay Hospitals, Catholic Healthcare West
    Inventor: Li-Xi Yang
  • Patent number: 7557118
    Abstract: A method for the preparation of a compound of general Formula: or pharmaceutically acceptable derivatives and salts, racemates, isomers and/or tautomers thereof comprising cyclizing an azomethine ylide of general Formula: wherein, A is a cyclic or non-cyclic group; Z is a carbon or a heteroatom; n is selected from 0, 1, 2 or 3; W, X and Y may be the same or different and each are selected from hydrogen; optionally substituted alkyl, alkenyl, alkynyl, amino, alkoxy, alkenoxy, alkynoxy, aryl, alkylthio, heterocyclyl; carboxy, carboxy ester, carboxamido, acyl, acyloxy, mercapto, halogen, nitro, sulfate, phosphate, cyano and optionally protected hydroxy; or W and X, together with the nitrogen and carbon atoms to which they are attached, form a saturated or unsaturated nitrogen containing heterocyclic group which may be optionally substituted or optionally fused to a saturated or unsaturated carbocyclic group, aryl group or heterocyclic group is provided.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: July 7, 2009
    Assignee: The Australian National University
    Inventors: Martin Gerhardt Banwell, Bernard Luke Flynn
  • Patent number: 7517891
    Abstract: The present invention relates to compositions and methods for preparing pharmaceutical compositions. In some embodiments, the invention includes compounds and methods of resolving chiral compounds. In some embodiments, the invention includes chiral and crystalline compositions and hydrates. In some embodiments, the invention contemplates compositions comprising camptothecin derivatives and synthetic intermediates thereof. In some embodiments, the invention includes methods of protecting, inserting, modifying, separating isomers, and removing chemical groups.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: April 14, 2009
    Assignee: Glyconix Corporation
    Inventor: Brian Keith Shull
  • Publication number: 20080255175
    Abstract: Compounds and compositions useful in methods for treating cancer in mammals. The compounds of the invention are of the formula: or a pharmaceutically acceptable salt, entantiomer or disastereomer thereof, wherein the “A” ring is a nitrogen-aryl group; each occurrence of Y is independently oxygen or H2; Z is oxygen or —CH2—; X is nitrogen or —CH; R1, R2, R3, R4, R5, R6, and R7 are subsitutents; n is an integer from 1-7; m is an integer having a value of 1-5; and the dotted line represents an optional bond.
    Type: Application
    Filed: April 16, 2007
    Publication date: October 16, 2008
    Inventors: Marina K. Lam, Kwok-Leung Shum, Wei Sun
  • Patent number: 7396837
    Abstract: New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: July 8, 2008
    Assignee: Pharma Mar, S.A.U.
    Inventors: Christian Bailly, Andrés Francesch, Maria Cristina Mateo Urbano, José Antonio Jiménez Guerrero, Alfredo Pastor Del Castillo, Carmen Cuevas Marchante
  • Publication number: 20080125451
    Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
    Type: Application
    Filed: September 12, 2007
    Publication date: May 29, 2008
    Applicant: AMR TECHNOLOGY, INC.
    Inventors: Mark A. WOLF, Peter R. GUZZO, Ian L. SCOTT
  • Publication number: 20080119502
    Abstract: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
    Type: Application
    Filed: September 12, 2007
    Publication date: May 22, 2008
    Applicant: AMR TECHNOLOGY, INC.
    Inventors: Mark A. WOLF, Peter R. GUZZO, Ian L. SCOTT
  • Patent number: 7354918
    Abstract: The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I) in which R represents a radical —AR? wherein A represents a heteroatom and R? represents a group selected from the group comprising linear or branched C1-C6 alkyl radicals, C2-C6 alkenyls, C2-C6 alkynyls, arylalkyls; esters comprising the formula —R1— CO—O—R2; amides comprising the formula —R3—CO—NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula —NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 8, 2008
    Assignee: Biocortech
    Inventors: Paola Ciapetti, Laurence Deyon, Camille-Georges Wermuth, Jean-François Pujol, Dinah Weissmann
  • Patent number: 6835807
    Abstract: A drug complex useful as a DDS compound, which is represented by the following formula: A-R—NH—Y—CH2—O—CO-Q, wherein A is a polymer as a drug carrier; R is a spacer, wherein the spacer is an amino acid or an oligopeptide comprising 2 to 8 amino acids; Y is phenylene group which may be substituted; and Q is a residue of a drug compound such as antineoplastic agents. The complex provides rapid and site-selective release of a drug compound such as antineoplastic or anti-inflammatory agents and surely exhibits expected efficacy.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: December 28, 2004
    Assignee: Daiichi Pharmaceuticals Co., Ltd.
    Inventors: Hiroshi Susaki, Kazuhiro Inoue, Hiroshi Kuga
  • Publication number: 20040235878
    Abstract: The key intermediate in any synthesis of Irinotecan is 7-ethyl-10-hydroxy-20(S)-camptothecin. A process for the efficient synthesis of this intermediate is demonstrated proceeding through readily available 20(S)-camptothecin. Various other tecan compounds may be made by use of corresponding 7-alkyl-10-hydroxy-20(S)-camptothecin intermediates.
    Type: Application
    Filed: May 12, 2004
    Publication date: November 25, 2004
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Chien-Hsing Lin, Yung-Fa Cheng, Kau-Ming Cheng
  • Patent number: 6811996
    Abstract: A drug delivery system compound comprising a carboxy(C1-4)alkyldextran polyalcohol modified with a saccharide compound and a residue of drug compound bound to the carboxy(C1-4)alkyldextran polyalcohol, and a method for measuring a drug delivery system compound in which a polymer carrier and a residue of drug compound are bound to each other by a spacer comprising 2 to 8 amino acids linked by peptide bond(s), which comprises treating the drug delivery system compound with a peptidase, and measuring the resulting hydrolysate.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: November 2, 2004
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Inoue, Hiroshi Kuga, Yoshinobu Shiose, Hiroshi Korenaga
  • Publication number: 20040198760
    Abstract: The present invention relates to pharmaceutically acceptable salts formed by the compounds of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said pharmaceutically acceptable salts, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and pharmaceutical compositions containing them.
    Type: Application
    Filed: March 23, 2004
    Publication date: October 7, 2004
    Inventors: Sairam Pothukuchi, Subrahmanyam Duvvuri, Sriram Rajagopal
  • Publication number: 20040192917
    Abstract: The present invention relates to an improved and economical process for the isolation of anticancer agent Camptothecin from the twigs and stem of Nothapodytes foetida using hot extraction 20(S) Camptothecin is an alkaloid, which contains a pentacyclic ring system that includes a pyrrolo [3,4-b] quinoline moiety (ring A, B and C), the pyridone ring D and a chiral centre at C-20 in ring E.
    Type: Application
    Filed: March 31, 2003
    Publication date: September 30, 2004
    Inventors: Santosh Kumar Srivastava, Merajuddin Khan, Suman Preet Singh Khanuja
  • Patent number: 6756381
    Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having an IR spectrum with an absorption centered between 3625 cm−1 and 3675 cm−1 and containing more than a trace of water.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: June 29, 2004
    Assignee: SuperGen, Inc.
    Inventors: Sanjeev Redkar, Ashok Gore
  • Publication number: 20040087609
    Abstract: Problem: A large scale production of camptothecin, which is a starting compound of irinotecan hydrochloride and various camptothecin derivatives, at a low cost and with ease.
    Type: Application
    Filed: November 25, 2002
    Publication date: May 6, 2004
    Inventors: Takashi Yaegashi, Takanori Ogawa, Seigo Sawada
  • Patent number: 6709679
    Abstract: Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS—, HO— or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5′-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=—NH2, —OH, —COOH, —O—CO—R—COR*, —NH—CO—R—COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R*H, phenyl, alkyl with 1-6 carbon atoms.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: March 23, 2004
    Inventor: Felix Kratz
  • Patent number: 6699876
    Abstract: Compound of formula (I): wherein: n is 0, 1 or 2, R1 represents (C3-C11)cycloalkyl or (C3-C11)cycloalkylalkyl, R2, R3, R4 and R5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH2)p—NaRb and —O—C(O)—N—RaRb, with p, Ra and Rb being as defined in the description, or two adjacent groups R2, R3, R4 and R5 together form a group —O—(CH2)t—O, t being integer from 1 to 3, R60, R70n, R80 and R90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R61, R71n, R81, and R91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: March 2, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, Ghanem Atassi, John Hickman, Bernard Cimetiere
  • Publication number: 20040018988
    Abstract: Camptothecin derivatives of camptothecin of formula (I) 1
    Type: Application
    Filed: March 17, 2003
    Publication date: January 29, 2004
    Applicants: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituo Nazionale per lo Studio e la Cura dei Tumori
    Inventors: Sabrina Dallavalle, Sergio Penco, Claudio Pisano, Franco Zunino
  • Publication number: 20030220245
    Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
    Type: Application
    Filed: March 24, 2003
    Publication date: November 27, 2003
    Inventors: Jeffrey A Hubbell, Donald Elbert, Ronald Schoenmakers
  • Publication number: 20030216421
    Abstract: Cascade esters of camptothecin are described. Processes for making these compounds and for using them in cancer treatment are also described.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 20, 2003
    Inventors: Zhisong Cao, Beppino C. Giovanella
  • Publication number: 20030212087
    Abstract: Halo-alkyl esters of camptothecin are described. Processes for making these compounds and for using them in cancer treatment, are also described.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 13, 2003
    Inventors: Zhisong Cao, Beppino C. Giovanella
  • Publication number: 20030181476
    Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having an IR spectrum with an absorption centered between 3625 cm−1 and 3675 cm−1 and containing more than a trace of water.
    Type: Application
    Filed: February 21, 2002
    Publication date: September 25, 2003
    Inventors: Sanjeev Redkar, Ashok Gore
  • Publication number: 20030171303
    Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amenable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug compounds and methods for synthesizing these 1-acyl-alkyl derivatives.
    Type: Application
    Filed: June 11, 2002
    Publication date: September 11, 2003
    Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
  • Publication number: 20030166671
    Abstract: Amorphous forms of 9-nitrocamptothecin are provided by grinding or pulverizing different polymorphic forms of 9-nitrocamptothecin, and the polymorphic forms are characterizable as having an X-ray powder diffraction pattern with discernable diffraction lines at different °2&thgr; values for Cu K&agr; radiation having a wavelength of 1.5406 Angstrom.
    Type: Application
    Filed: October 8, 2002
    Publication date: September 4, 2003
    Inventors: Sanjeev Redkar, Ashok Gore
  • Patent number: 6608052
    Abstract: Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: August 19, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Steffen Breitfelder, Pier F. Cirillo, John R. Regan
  • Publication number: 20030135049
    Abstract: A process for preparing S type 2-substituted hydroxy-2-indolidinylbutyric ester compound [II]: 1
    Type: Application
    Filed: January 8, 2003
    Publication date: July 17, 2003
    Applicant: TANABE SEIYAKU CO., LTD.
    Inventors: Takayuki Kawaguchi, Sumihiro Nomura, Kenji Tsujihara
  • Publication number: 20030105109
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: November 20, 2002
    Publication date: June 5, 2003
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, Ghanem Atassi, John Hickman, Bernard Cimetiere
  • Publication number: 20030088101
    Abstract: A compound has the formula 1
    Type: Application
    Filed: June 6, 2002
    Publication date: May 8, 2003
    Inventors: Dennis P. Curran, Bom David, Thomas G. Burke
  • Patent number: 6534515
    Abstract: A compound selected from the group consisting of all possible isomers or racemates of a compound of the formula wherein the various substituents are as defined in the specification and its non-toxic, pharmaceutically acceptable salts with acids or bases having anti-anoxic, anti-ischemic and neuronal protective anti-depressant activities.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: March 18, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: François Clemence, Jean-Luc Haesslein, Claude Oberlander
  • Patent number: 6509345
    Abstract: Compound of formula (I): wherein: n is 0, 1 or 2, R1, R2, R3, R4 and R5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH2)p—NRaRb and —O—C(O)—N—RaRb, with p, Ra and Rb being as defined in the description, or two adjacent groups R2, R3, R4 and R5 together form a group —O—(CH2)t—O, t being an integer from 1 to 3, R60, R70n, R80 and R90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R61, R71n, R81 and R91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: January 21, 2003
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, Ghanem Atassi, John Hickman, Bernard Cimetiere
  • Publication number: 20030004150
    Abstract: A compound of the formula 1
    Type: Application
    Filed: February 6, 2002
    Publication date: January 2, 2003
    Inventors: Dennis Bigg, Olivier Lavergne, Francesc Pla Rodas, Jacques Pommier, Gerard Ulibarri, Jerry Harnett, Alain Rolland, Anne-Marie Liberatore, Christophe Lanco, Jean-Bernard Cazaux, Christine Le Breton, Eric Manginot
  • Publication number: 20020077325
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: November 5, 2001
    Publication date: June 20, 2002
    Inventors: Gilbert Lavielle, Patrick Hautefaye, Alain Pierre, Ghanem Atassi, John Hickman, Bernard Cimetiere
  • Patent number: 6407239
    Abstract: Aromatic camptothecin ester compounds having the formula: are described as well as formulations containing the compounds. Methods of treating cancer and/or tumors are also disclosed.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: June 18, 2002
    Assignee: The Stehlin Foundation For Cancer Research
    Inventors: Zhisong Cao, Beppino C. Giovanella
  • Patent number: 6376617
    Abstract: Water soluble polymeric conjugates of camptothecin consist essentially of N-(2-hydroxypropyl)methacryloylamide units linked via a spacer group to a residue of a camptothecin such as irinotecan or its non-soluble metabolite, 7-ethyl-10-hydroxy-camptothecin. The conjugates possess enhance antitumor activity and decreased toxicity with respect to the free drug. A process for their preparation and the pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: April 23, 2002
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Francesco Angelucci, Gabriele Fachin, Valeria Caiolfa, Antonino Suarato
  • Publication number: 20020045637
    Abstract: A compound selected from the group consisting of all possible isomers or racemates of a compound of the formula 1
    Type: Application
    Filed: April 15, 1994
    Publication date: April 18, 2002
    Inventors: FRANCOIS CLEMENCE, JEAN-LUC HAESSLEIN, CLAUDE OBERLANDER
  • Publication number: 20020032331
    Abstract: Water soluble polymeric conjugates of camptothecin consist essentially of N-(2-hydroxypropyl)methacryloylamide units linked via a spacer group to a residue of a camptothecin such as irinotecan or its non-soluble metabolite, 7-ethyl-10-hydroxy amptothecin. The conjugates possess enhance antitumor activity and decreased toxicity with respect to the free drug. A process for their preparation and the pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: June 3, 1999
    Publication date: March 14, 2002
    Inventors: FRANCESCO ANGELUCCI, GABRIELE FACHIN, VALERIA CAIOLFA, ANTONINO SUARATO
  • Publication number: 20020019343
    Abstract: Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS—, HO— or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5′-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=—NH2, —OH, —COOH, —O—CO—R—COR*, —NH—CO—R—COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.
    Type: Application
    Filed: August 20, 2001
    Publication date: February 14, 2002
    Inventor: Felix Kratz
  • Patent number: 6306868
    Abstract: Compounds of formula (I), wherein: R1 is —CN, —CH(CN)—R4, —CH═C(CN)—R4, —CH2—CH(CN)—R4, —C(═NOH)—NH2, —C(═NH)—NH2, —CH═C(NO2)—R4, —CH(CN)—R5, —CH(CH2NO2)—R5; 5-tetrazolyl, 2-(4,5-dihydrooxazolyl), 1,2,4-oxadiazolin-3-yl-5-one; R2 is hydrogen; R3 is hydrogen, OR6; R4 is hydrogen, C1-C6 linear or branched alkyl, CN, COOR7; R5 is hydrogen, OR8; R6 is hydrogen, C1-C6 linear or branched alkyl, (C6-C12) aryl (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl, (C1-C4) alkyl (C6-C12) aryl, (C6-C12) aryl (C2-C4) acyl, (C2-C4) acyl, amino (C1-C4) alkyl, amino (C2-C4) acyl, glycosyl; R7 is hydrogen, C1-C6 linear or branched alkyl, (C6-C12) aryl (C1-C4) alkyl, (C1-C4) alkoxy (C1-C4) alkyl, (C1-C4) alkyl (C6-C12) aryl; R8 has the same meanings of R6, independently of the latter. These compounds are active as topoisomerase I inhibitors and can be used as antitumor drugs.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: October 23, 2001
    Assignee: Istituto Nazionale per Lo Studio e la Cura Dei Tumori
    Inventors: Lucio Merlini, Sergio Penco, Franco Zunino
  • Patent number: RE37449
    Abstract: The present invention relates to the synthesis of dimer alkaloid compounds, particularly those of the Catharantus (Vinca) family, from an indole unit, such as cantharanthine, and a dihydroindole unit, such as vindoline. A multi-step process is disclosed including the steps of (1) of 1,4-reduction of a first dimeric iminium intermediate to an enamine compound by reaction with a 1,4-dihydropyridine compound; (2) oxidative transformation of the resulting enamine to a second iminium intermediate under controlled aeration; (3) reduction of the second iminium intermediate to form the target dimer alkaloid compounds. The entire process can be conducted in a one-pot operation to obtain the target compounds without isolation of the intermediates.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: November 13, 2001
    Assignee: University of British Columbia
    Inventors: James P. Kutney, Lewis S. L. Choi, Jun Nakano, Hiroki Tsukamoto, Camille A. Boulet, Michael McHugh